Clinical Advances in Hematology & Oncology

A review of essential thrombocythemia and its complications

Annals of Oncology

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Cancer Medicine

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project

American Journal of Hematology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Cancer Medicine

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia

British Journal of Hematology

Characterization of myeloproliferative neoplasms in the paediatric and young adult population

Journal of the American Heart Association

In‐hospital outcomes of acute myocardial infarction with essential thrombocythemia and polycythemia vera: Insights from the National Inpatient Sample

The Lancet

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

2022 American Society of Hematology Annual Meeting Abstract

Ropeginterferon alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of Low-PV randomized phase II trial

2022 American Society of Hematology Annual Meeting Abstract

Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis